Fulltext:
245679.pdf
Embargo:
until further notice
Size:
5.815Mb
Format:
PDF
Description:
Publisher’s version
Publication year
2021Source
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology, 13, 6, (2021), article e1719ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Internal Medicine
Journal title
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
Volume
vol. 13
Issue
iss. 6
Subject
Radboudumc 19: Nanomedicine RIMLS: Radboud Institute for Molecular Life Sciences; Internal Medicine - Radboud University Medical CenterAbstract
Immunotherapy has firmly established itself as a compelling avenue for treating disease. Although many clinically approved immunotherapeutics engage the adaptive immune system, therapeutically targeting the innate immune system remains much less explored. Nanomedicine offers a compelling opportunity for innate immune system engagement, as many nanomaterials inherently interact with myeloid cells (e.g., monocytes, macrophages, neutrophils, and dendritic cells) or can be functionalized to target their cell-surface receptors. Here, we provide a perspective on exploiting nanomaterials for innate immune system regulation. We focus on specific nanomaterial design parameters, including size, form, rigidity, charge, and surface decoration. Furthermore, we examine the potential of high-throughput screening and machine learning, while also providing recommendations for advancing the field. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
This item appears in the following Collection(s)
- Academic publications [245131]
- Electronic publications [132467]
- Faculty of Medical Sciences [93207]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.